Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell.

Slides:

Advertisements

Similar presentations

Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with.

Advertisements

Thrombotic Microangiopathy Associated with Sirolimus Level after Allogeneic Hematopoietic Cell Transplantation with Tacrolimus/Sirolimus-Based Graft-versus-Host.

Mismatch on Glutathione S-Transferase T1 Increases the Risk of Graft-versus-Host Disease and Mortality after Allogeneic Stem Cell Transplantation María.

Incidence and Causes of Hospital Readmission in Pediatric Patients after Hematopoietic Cell Transplantation David Stephen Shulman, Wendy B. London, Dongjing.

Increased Levels of Tumor Necrosis Factor α Are Associated with an Increased Risk of Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Graft-Versus-Host Disease and Survival after Cord Blood Transplantation for Acute Leukemia: A Comparison of Japanese versus White Populations Yachiyo.

Single and Multiple Dose MultiStem (Multipotent Adult Progenitor Cell) Therapy Prophylaxis of Acute Graft-versus-Host Disease in Myeloablative Allogeneic.

Chimerism studies in HLA-identical nonmyeloablative hematopoietic stem cell transplantation point to the donor CD8+ T-cell count on day +14 as a predictor.

Outcome of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Hematopoietic Cell Transplant Recipients Receiving Aerosolized Ribavirin: Significance.

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Extended Mycophenolate Mofetil and Shortened Cyclosporine Failed to Reduce Graft- versus-Host Disease after Unrelated Hematopoietic Cell Transplantation.

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Human Herpesvirus-6B Reactivation Is a Risk Factor for Grades II to IV Acute Graft- versus-Host Disease after Hematopoietic Stem Cell Transplantation:

A First-in-Disease Trial of in Vivo Costimulation Blockade for GVHD Prevention: The Addition of Abatacept to Standard GVHD Prophylaxis Controls Early.

Albuminuria in Hematopoietic Cell Transplantation Patients: Prevalence, Clinical Associations, and Impact on Survival Sangeeta R. Hingorani, Kristy Seidel,

Sabina Kersting, Leo F. Verdonck

Phase I Study of Urate Oxidase in the Reduction of Acute Graft-Versus-Host Disease after Myeloablative Allogeneic Stem Cell Transplantation Albert C.

Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer Brigitta Omazic, Mats Remberger, Lisbeth Barkholt, Gunnar.

Significance of Ethnicity in the Risk of Acute Graft-versus-Host Disease and Leukemia Relapse after Unrelated Donor Hematopoietic Stem Cell Transplantation

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

Plasma Biomarkers in Graft-versus-Host Disease: A New Era?

Betty T. Tran, Abigail Halperin, Jason W. Chien

Increased Programmed Death-1 Molecule Expression in Cytomegalovirus Disease and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation

Donor-to-Recipient ABO Mismatch Does Not Impact Outcomes of Allogeneic Hematopoietic Cell Transplantation Regardless of Graft Source Sharat Damodar,

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic.

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Cotransplantation of Mesenchymal Stem Cells Might Prevent Death from Graft-versus- Host Disease (GVHD) without Abrogating Graft-versus-Tumor Effects after.

Biology of Blood and Marrow Transplantation

Rituximab Treatment before Reduced-Intensity Conditioning Transplantation Associates with a Decreased Incidence of Extensive Chronic GVHD Suzanne van.

John Kuruvilla, John D. Shepherd, Heather J. Sutherland, Thomas J

Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome Haesook T. Kim, Philippe Armand,

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease Divaya.

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Graft-versus-Host Disease Induced Graft-versus-Leukemia Effect: Greater Impact on Relapse and Disease-Free Survival after Reduced Intensity Conditioning

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Preengraftment Serum C-Reactive Protein (CRP) Value May Predict Acute Graft-versus- Host Disease and Nonrelapse Mortality after Allogeneic Hematopoietic.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Costs of Hematopoietic Cell Transplantation: Comparison of Umbilical Cord Blood and Matched Related Donor Transplantation and the Impact of Posttransplant.

Pharmacoeconomic Analysis of Palifermin to Prevent Mucositis among Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation Ajay K. Nooka,

Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.

Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant.

Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts Kile Green, Kim Pearce, Rob.

Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom Haesook T. Kim, Philippe Armand Biology of Blood.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

Allogeneic Transplantation for Adult Acute Leukemia in First and Second Remission with a Novel Regimen Incorporating Daily Intravenous Busulfan, Fludarabine,

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance Deborah.

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Double Umbilical Cord Blood Transplantation after Novel Myeloablative Conditioning Using a Regimen of Fludarabine, Busulfan, and Total Lymphoid Irradiation

Decreased Serum Albumin as a Biomarker for Severe Acute Graft-versus-Host Disease after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation

High Incidence of Severe Acute Graft-Versus-Host Disease with Tacrolimus and Mycophenolate Mofetil in a Large Cohort of Related and Unrelated Allogeneic.

A Randomized Double-Blind Trial of Hydroxychloroquine for the Prevention of Chronic Graft-versus-Host Disease after Allogeneic Peripheral Blood Stem Cell.

Graft-versus-Host Disease Prophylaxis with Tacrolimus and Mycophenolate Mofetil in HLA-Matched Nonmyeloablative Transplant Recipients Is Associated with.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

C-Reactive Protein Levels at Diagnosis of Acute Graft-versus-Host Disease Predict Steroid-Refractory Disease, Treatment-Related Mortality, and Overall.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant.

Long-term Outcome of Hodgkin Disease Patients Following High-Dose Busulfan, Etoposide, Cyclophosphamide, and Autologous Stem Cell Transplantation—A Similar.

Monitoring Mixed Lineage Leukemia Expression May Help Identify Patients with Mixed Lineage Leukemia–Rearranged Acute Leukemia Who Are at High Risk of.

Prospective Monitoring of Tumor Necrosis Factor α and Interferon γ to Predict the Onset of Acute and Chronic Graft-versus-Host Disease after Allogeneic.

Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity.

Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.

Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation Daniel R Couriel,

Longitudinal Assessment of Morbidity and Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Retrospective Analysis of a.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation H Khoury, K Trinkaus, M.J Zhang, D Adkins,

Andrew R. Rezvani, Barry E. Storer, Katherine A. Guthrie, H

Presentation transcript:

Peritransplantation Red Blood Cell Transfusion Is Associated with Increased Risk of Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Sakura Hosoba, Edmund K. Waller, Neeta Shenvi, Michael Graiser, Kirk A. Easley, Zaid Al-Kadhimi, Akira Andoh, Ana G. Antun, Sheliagh Barclay, Cassandra D. Josephson, Jean L. Koff, H. Jean Khoury, Amelia A. Langston, James C. Zimring, John D. Roback, Cynthia R. Giver Biology of Blood and Marrow Transplantation Volume 24, Issue 5, Pages 973-982 (May 2018) DOI: 10.1016/j.bbmt.2018.01.003 Copyright © 2018 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Development of grade III/IV aGVHD and early mortality in the allo-HSCT recipients. (A) Calculated cumulative incidence curves of competing risks of grade III-IV aGVHD (blue) and mortality without grade III-IV aGVHD (red) within 150 days post-transplantation. The cumulative incidence function (CIF) subdistribution hazards for grade III-IV aGVHD and mortality at days +30 and +60 post-transplantation are shown beneath. (B) Increasing frequencies of patients diagnosed with grade I, II, and III-IV aGVHD to day +150 post-transplantation (P = .022, t test comparing onset times for grade I versus grade III/IV aGVHD). The gray bar from day −7 to day +27 post-transplantation represents the time frame during which RBC and platelet transfusions were tallied. Biology of Blood and Marrow Transplantation 2018 24, 973-982DOI: (10.1016/j.bbmt.2018.01.003) Copyright © 2018 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Overall survival was associated with aGVHD grade and number of RBC units and platelet units transfused from day −7 to day +27 in Kaplan-Meier analyses. (A) Kaplan-Meier analyses of cumulative survival comparing patients with grade 0/I (blue), II (yellow), and III-IV (maroon) aGVHD. (B) Cumulative survival of patients transfused with >5 RBC units (yellow) versus ≤5 RBC units (blue). (C) Cumulative survival of patients transfused with >2 platelet units (yellow) versus ≤2 platelet units (blue). Plots are truncated at 7 years post-transplantation. Biology of Blood and Marrow Transplantation 2018 24, 973-982DOI: (10.1016/j.bbmt.2018.01.003) Copyright © 2018 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Weekly frequencies of patients receiving RBC transfusions patients differed based on patient characteristics and aGVHD severity. (A) Cumulative incidence of patients who received RBC transfusions as grouped by ABO match between transplant recipient and donor. (B-D) Percentages of patients receiving RBC transfusions each week (−1 week to +4 weeks post-transplantation) as grouped by ABO match between transplant recipient and donor (B), conditioning regimen intensity (NMA, nonmyeloablative; RIC, reduced intensity conditioning; MAC, myeloablative conditioning) (C), and aGVHD severity (D). *P < .05; **P < .01; ***P < .001. Biology of Blood and Marrow Transplantation 2018 24, 973-982DOI: (10.1016/j.bbmt.2018.01.003) Copyright © 2018 The American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Causes of death in 4 patient groups based on RBC and platelet transfusions. Groups that received more RBC transfusions had higher frequencies of GVHD-related mortality. Patients were grouped based on the number of total RBC and platelet units received from day −7 to +27 post-transplantation, excluding those received after a diagnosis of aGVHD (>5 versus ≤5 RBC units, and > 2 versus ≤2 platelet units). Pie chart sizes are proportional to the percent mortality in each group. Biology of Blood and Marrow Transplantation 2018 24, 973-982DOI: (10.1016/j.bbmt.2018.01.003) Copyright © 2018 The American Society for Blood and Marrow Transplantation Terms and Conditions